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ABSTRACT
Objective: In a budget-constrained health-care system, decisions about
investing in strategies to promote implementation have to be made along-
side decisions about health-care provision and research funding. Using a
Bayesian decision-theoretic approach, an analytic framework has been
developed to inform these separate but related decisions, establishing the
expected value of both perfect information (EVPI) and perfect implemen-
tation (EVPIM). We applied this framework to inform decision-making
about resource allocation to metastatic hormone-refractory prostate
cancer (mHRPC) in the UK.
Methods: Based on available evidence on the cost-effectiveness of all
plausible treatments for mHRPC, we determined which treatment
option(s) were cost-effective and explored the uncertainty surrounding this
decision. Given the decision uncertainty and the variation in care provided
by health-care professionals, we then determined the EVPI and EVPIM.
Finally, we performed sensitivity analyses to explore the inﬂuence of
alternative assumptions regarding various decision parameters on the efﬁ-
ciency of resource allocation.
Results: Depending on the cost-effectiveness threshold (l), we identi-
ﬁed mitoxantrone plus prednisone/prednisolone and docetaxel plus
prednisone/ prednisolone (3 weekly) as the optimal treatments for
mHRPC. Given current clinical practice, there appears to be consider-
able scope for improving the efﬁciency of health-care provision: the
EVPI (estimated to be over £13 million) indicates that acquiring further
information could be cost-effective; and the EVPIM (estimated to be
over £4 million) suggests that investing in strategies to implement the
treatments regimens being identiﬁed as optimal is potentially worth-
while. Through sensitivity analyses, we found that the EVPI and EVPIM
are mainly driven by l, the number of treatment options being con-
sidered, the current level of implementation, and the size of the eligible
patient population.
Conclusion: The application demonstrates that the framework provides a
simple and useful analytic tool for decision-makers to address resource
allocation problems between health-care provision, further research, and
implementation efforts.
Keywords: bayesian analysis, health-care decision-making, value of imple-
mentation, value of information analysis.
Introduction
Given the growing demand for health-care services and the
limited resources to deliver them, health-care decision-makers
are increasingly confronted with resource allocation problems.
Decision-makers commonly rely on economic evaluations to
provide evidence about the likely costs, effects, and cost-
effectiveness of health-care technologies, such as diagnostic
instruments, treatment regimens or clinical practice guidelines
[1]. The decision whether or not to reimburse a technology is
inevitably made in a context of uncertainty surrounding the
cost-effectiveness of these technologies [2,3]. To reduce uncer-
tainty associated with the reimbursement decision, decision-
makers could opt to commit resources to collecting additional
economic evidence on technologies [4,5]. Bayesian value-of-
information analysis provides an explicit and rigorous frame-
work within which related decisions regarding technology
reimbursement and research funding can be addressed [6–9].
The implicit assumption within decision analyses and value of
information analyses is that health-care technologies automati-
cally get implemented into clinical practice. Nonetheless, irre-
spective of the rigor of economic evidence on the technologies for
which decision-makers issue guidance, patients and health-care
professionals may not to adhere to guidance [10–13]. Nonadher-
ence to cost-effective technologies compromises the efﬁciency of
health-care provision in terms of the health and resources
forgone. Implementation strategies, including education or out-
reach visits, reminders, and ﬁnancial incentives, aim to change
adherence but cost money to enact. In a budget-constrained
health-care system, decisions about investing in strategies to
promote implementation have to be made alongside decisions
about health-care provision and research funding, and decision-
makers should carefully consider the potential worth of imple-
mentation efforts to decide whether to adopt strategies [14–17].
The established methodology for exploring the economics of
technology implementation has tended to concentrate on study-
ing the cost-effectiveness of alternative implementation strategies
rather than assessing the economic impact of nonadherence,
let alone considering the efﬁciency of investment in health-care
provision and/or further information collection [17–21].
Recently, an analytic framework was developed to inform the
conceptually distinct but related decisions about health-care
provision, research funding, and investments in implementation
efforts [22]. Using a Bayesian decision-theoretic approach, the
framework establishes cost-effective health-care provision and
the maximum returns to investment in further research (through
the expected value of perfect information) and implementa-
tion efforts (through the expected value of perfect implementa-
tion). Nonetheless, these upper bounds provide only necessary
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conditions for collecting additional information and/or ensuring
implementation and should be compared to the costs of these
activities to determine whether they are potentially worthwhile.
The sufﬁcient condition for the worth of research funding requires
that the expected value of additional or sample information
(EVSI) exceeds the costs of the speciﬁc research [7,8,23–25].
Similarly, decision-makers need to consider the additional beneﬁts
and the additional costs of speciﬁc implementation strategies to
decide whether technology implementation will in fact be worth-
while [26,27].
In this article, we aim to demonstrate the use and practicality
of this analytic framework by applying it prospectively alongside
a technology appraisal to inform the National Institute for
Health and Clinical Excellence (NICE), the body providing
guidance for the National Health Service (NHS) in England
and Wales, about the allocation of health-care resources for
metastatic hormone-refractory prostate cancer (mHRPC). The
article starts with an outline of the various decision-theoretic
approaches to inform the resource allocation decisions and the
analytic framework developed by Fenwick et al. [22]. The appli-
cation of the framework is then demonstrated, providing a
detailed description of the background, the methods, and the
results of the decision analysis. We conclude with a discussion of
the main ﬁndings of the analysis and the implications for
decision-making as well as some comments on the framework
and several suggestions for its extension.
Methodological Background
Resource Allocation Decisions
There are three questions which any health-care system needs to
address in making decisions about the efﬁcient allocation of
health-care resources: 1) whether it is cost-effective to reimburse
a health-care technology, given available evidence (reimburse-
ment decision); 2) whether it is worthwhile funding further
research to collect additional information to inform the reim-
bursement decision in the future (research decision); and 3)
whether it is worthwhile investing in strategies to promote the
implementation of the reimbursed technology (implementation
decision). To inform these conceptually separate but related deci-
sions, various decision-theoretic approaches to health economic
evaluation are of use.
Reimbursement decision. If a health-care system’s objective is to
maximize health gain subject to a budget constraint, then the
decision about whether to reimburse a health-care technology,
given currently available information, should be based on the
expected cost-effectiveness (or mean net beneﬁts) [23]. Inference
and the distribution of the expected cost-effectiveness (or mean
net beneﬁts) are irrelevant to the technology choice [7]. For
a decision involving j (mutually exclusive) technologies where
the cost-effectiveness (or net beneﬁt) is dependent on a set of
unknown parameters q, the technology with the maximum
expected cost-effectiveness (or mean net beneﬁts [maxj Eq NB(j,
q)]) should be chosen [23]. Nonetheless, several authors have
recently demonstrated the importance of also considering the
value of additional information forgone [28], and the (opportu-
nity) costs of reversal or delay [25] when informing decision-
making about technology reimbursement. More details on the
latter are described in the discussion.
Research decision. Although the uncertainty in the expected cost-
effectiveness (or mean net beneﬁts) may not be relevant to the
reimbursement decision, it is essential for the decision about
whether the gathering of additional information is warranted
[7,8,23–25]. Given the uncertainty surrounding the decision to
reimburse a technology, there is a probability of making the
wrong decision. If the wrong decision about reimbursement is
made, there will be costs in terms of health gain and resource
savings forgone (i.e., opportunity loss). The expected cost of
decision uncertainty is determined by the error probability asso-
ciated with the reimbursement decision and the opportunity loss
of a wrong decision. Value of information analysis evaluates the
extent to which additional evidence might improve decision-
making by reducing the chance for error and compares that
improvement (in terms of reduced expected costs of uncertainty)
with the cost of information. The expected value of perfect
information (EVPI) provides a maximum return to investment in
further research (i.e., the difference between the expected value of
a decision made on the basis of available evidence [maxj Eq NB(j,
q)] and that on the basis of perfect information [Eq maxj NB(j,
q)]), because perfect information eliminates all the possibility of
making the wrong decision [8,23]. The EVPI can be calculated for
individual or various combinations of parameters to assess the
potential worth of research concerning particular elements of the
decision [3,23]. If the EVPI exceeds the expected costs of further
investigation, then it is potentially cost-effective to acquire more
information by conducting additional research (i.e., a necessary
condition for research funding) [8,23]. Evidently, to establish a
sufﬁcient condition for deciding whether further research will be
worthwhile and identifying technically efﬁcient research scale and
design, the marginal beneﬁts (i.e., EVSI) and the marginal costs of
sample information need to be considered, and the expected net
beneﬁt of sampling (ENBS) should be estimated [7,8,23–25]. In
calculating the EVSI, the expected research cost, and the ENBS of
trialing, it is advocated to account for the timing of future
research, including time for accrual, follow-up, and analysis
[7,24,25,29,30].
Implementation decision. Health-care technologies that are
deemed cost-effective (or beneﬁcial) do not automatically or
immediately get implemented perfectly into clinical practice
[13,31]. Nonadherence to technologies by patients and health-
care professionals may be caused by multiple factors such as
knowledge, attitude or even chance [32,33]. Less than perfect
implementation of cost-effective technologies reduces the efﬁ-
ciency of the health-care system [22]. The expected efﬁciency
losses are determined by the level of implementation, i.e., adher-
ence to technology j (denoted by rj) and by the expected cost-
effectiveness (or mean net beneﬁts) of the technologies being
considered. The expected value of perfect implementation
(EVPIM) is simply the difference between the expected value of a
decision that is implemented perfectly (maxj Eq NB(j, q)) and that
with implementation at its current level (Srj * Eq NB(j, q)). The
EVPIM provides a measure of the upper bound on the value of
reimbursing implementation strategies to change adherence to
cost-effective health-care technologies. If the EVPIM exceeds the
expected implementation costs, then it is potentially worthwhile
to ensure technology implementation, and a necessary condition
for investing in implementation is established. Analogous to the
concepts of EVPI, EVSI, and ENBS, the sufﬁcient condition for
the worth of promoting the implementation of valuable tech-
nologies into clinical practice requires that the expected value of
speciﬁc implementation strategies (EVSIM) exceeds the costs of
the implementation efforts [26,27].
Decision Analytic Framework
The analytic framework developed by Fenwick et al. [22] com-
bines the various (Bayesian) decision theoretic approaches to
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explore both the value of information and the value of imple-
mentation (see Box 1).
Within the framework, the resource allocation decision
context is represented by a simple four-state world where both
information and implementation can be either at the current level
or perfect. The current level of information relates to the rigor of
currently available evidence, where a situation of perfect infor-
mation assumes that there is no uncertainty surrounding the
costs and effects of a health-care technology. The level of imple-
mentation depends on the adherence to the technologies in clini-
cal practice, and varies between 0% (i.e., perfect implementation
where the technology is not cost-effective) and 100% (i.e., perfect
implementation of a cost-effective technology). Each of the states
represents a certain expected value of a decision made, in terms
of net beneﬁts [34,35].
Through comparison and subtraction of the expected deci-
sion values of the different states, we can determine the EVPI
(D - C) and the EVPIM (C - A). In addition, the framework
allows the determination of the realizable expected value of
perfect information (rEVPI = B - A) and the expected value of
perfection (EVP = D - A). Assuming a relationship between the
availability and rigor of evidence and the level of implementation
( ′ρ j = f(level of information)), the rEVPI identiﬁes the expected
value of research that is realizable without reimbursing imple-
mentation strategies to change the adherence to cost-effective
technologies in clinical practice. The EVP is a combined measure
of the maximum possible return for an investment in research
and implementation, and identiﬁes the scope for improving the
efﬁciency of the health-care system in terms of the health that can
be generated subject to a given budget constraint.
Because decisions regarding health-care provision, research
funding, and implementation investments are to the public good,
the valuations for EVPI, rEVPI, EVPIM, and EVP should be
calculated across the population of (future) patients for whom
the decisions are relevant. Population level values can be estab-
lished based on estimates of the incidence of patients (I) in each
period (t) discounted at rate (r) [23].
On the basis of the expected population values of information
and implementation, decision-makers can address issues of 1)
which technologies to reimburse; 2) whether there is potential
worth associated with undertaking further research; and 3)
whether it is potentially worthwhile investing in strategies to
promote the implementation of cost-effective technologies.
Because these values (i.e., pEVPI, prEVPI, pEVPIM, and pEVP)
place an upper bound on the returns of efﬁciency improvement
through conducting further research and/or ensuring implemen-
tation, the framework provides necessary conditions for address-
ing resource allocation problems between health-care provision,
research funding, and implementation investments. Nonetheless,
to establish sufﬁcient conditions: decide whether further research
and/or ensuring implementation will be worthwhile and identify
efﬁcient design of speciﬁc research and speciﬁc implementation
Box 1 Framework and derivations of population EVPI, population realizable EVPI, population EVPIM, and population EVP.
Level of information
Current Perfect
Level of implementation
Current A B
Perfect C D
The framework matrix identiﬁes 4 states (A, B, C and D) that represent a certain expected value of a decision made on the basis
the level of information (current or perfect) and level of implementation (current or perfect). Comparison and subtraction of the
expected decision values of the different states yields the valuations for EVPI, rEVPI, EVPIM, and EVP.
The following equations apply to inform resource allocation decisions involving j technologies where net beneﬁt (NB) is
dependent on a set of unknown parameters q:
EVPI = D - C = Eq maxj NB(j, q) - maxj Eq NB(j, q)
rEVPI = B - A = E NB j E NB jj
j
j
j
θ θρ θ ρ θ′ ∗ ( ) − ∗ ( )∑ ∑, ,
EVPIM = C - A = maxj Eq NB(j, q) - Srj * Eq NB(j, q)
EVP = D - A = Eq maxj NB(j, q) - Srj * Eq NB(j, q)
The population values are determined by multiplying the relevant measure by a scaling factor representing the future population
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Where:
(p)EVPI = (population) expected value of perfect information
(p)rEVPI = (population) realizable expected value of perfect information
(p)EVPIM = (population) expected value of perfect implementation
(p)EVP = (population) expected value of perfection
rj = level of implementation, i.e., adherence to technology j, where ′ρ i = f(level of information); with
′ ≥ρ ρj j ∈ [0,1]
I = incidence in period t
t = period
T = total number of periods for which information from research would be useful
r = discount rate
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strategies, would still require that decision-makers estimate the
net beneﬁt of sampling (with EVSI > costs of the speciﬁc
research) [7,8,23–25] and the net beneﬁt of speciﬁc implementa-
tion strategies (with EVSIM > costs of the implementation
efforts) [26,27].
Application of Framework
Background Information
In the UK, prostate cancer is the second most common male
cancer, with age-standardized mortality rates over 27 per 100,000
men [36]. The majority of such deaths are in patients with
mHRPC, for whom the disease has become unresponsive to
hormone treatment after around 18 months and progressed [37].
Treatment aims to improve symptoms, slow progression of the
disease, and prolong life. The UK population of patients with
mHRPC is assumed to be 4122 (based on an annual population of
9161 patients, of which 30% are eligible for D + P, and a decision
time of 1.5 years) [36]; patient survival is not expected to exceed
12 months [38]. Although in some countries (e.g., in the USA,
along with other Western countries) a combination of mitox-
antrone and prednisolone (M + P) has come to be accepted as
standard care for this group of patients [39], there remains
uncertainty about which treatment option is most likely cost-
effective under different circumstances. Currently, clinical practice
varies considerably among health-care professionals, implement-
ing different treatment options, including second-line hormonal
therapy, chemotherapy with or without corticosteroids, and best
supportive care.
Methods
As part of a technology assessment commissioned by NICE to
inform its guidance for the NHS concerning mHRPC, an eco-
nomic model was developed [39] to compare the full range of
relevant treatment regimens, comprising:
• D + P (3 weekly): docetaxel (75 mg/m2 every 3 weeks) plus
prednisone/prednisolone (5 mg orally twice daily);
• M + P: mitoxantrone (12 mg/m2 every 3 weeks) plus
prednisone/prednisolone (5 mg orally twice daily);
• P: prednisone/prednisolone (5 mg orally twice daily);
• D + P (weekly): docetaxel (30 mg/m2 on days 1, 8, 15, 22,
and 29 in a 6-week cycle) plus prednisone/prednisolone
(5 mg orally twice daily);
• D + E: docetaxel (60–70 mg/m2 every 3 weeks) plus estra-
mustine (three times daily on days 1–5);
• D + E + P (70): docetaxel (70 mg/m2 every 3 weeks) plus
estramustine (840 mg in three divided doses on days 1–5
and 8–12) plus prednisone/prednisolone (5 mg orally twice
daily);
• D + E + P (35): docetaxel (35 mg/m2 twice every 3 weeks)
plus estramustine (840 mg in three divided doses on days
1–5 and 8–12) plus prednisone/prednisolone (5 mg orally
twice daily);
• M + P + C: mitoxantrone (12 mg/m2 every 3 weeks) plus
prednisone/prednisolone (5 mg orally twice daily) plus clo-
dronate (1500 mg over 3 hours every 21 days).
The model provides a framework for the synthesis of clinical
effectiveness and economic reviews to develop a single, uniﬁed
analysis of themain comparators identiﬁed, reporting estimates of
the incremental costs per life-years gained and quality-adjusted
life-years (QALYs). The analysis takes an NHS perspective and
uses a lifetime horizon. Further details of the model and the
analysis are available in Collins et al. [39].
Table 1 summarizes the currently available evidence on the
costs and effects of the eight potential treatments of mHRPC, and
denotes the current implementation of the different treatment
options into clinical practice.
To inform the 1) reimbursement decision, we ﬁrst determined
the incremental cost-effectiveness ratios (ICERs) for all plausible
treatment options, based on the modeled estimates of costs and
QALYs [39]. We illustrated the uncertainty surrounding this
decision using cost-effectiveness acceptability curves (CEACs)
and frontier (CEAF). The CEAC is a plot of the probability that
a treatment option is cost-effective as a function of the cost-
effectiveness threshold (l) [4]. The CEAF presents the same infor-
mation but only for the range of values for l where the treatment
option is deemed to be cost-effective (i.e., maximizes NB)
[40,41]. As such, the CEAF is a disjointed frontier constructed
from the individual CEACs of the cost-effective treatment
options, with the discontinuities occurring at the point at which
the decision switches from one treatment option to another (i.e.,
ICER). Where a treatment option is not deemed cost-effective on
the basis of expected values, it will not appear in the CEAF. The
CEAF does not, in itself, aid the reimbursement decision; it
simply presents the probability that the treatment option deemed
cost-effective on the basis of expected values is in fact cost-
effective. The complement of the CEAF provides the probability
that the decision is incorrect (error probability) and the treatment
option deemed cost-effective on the basis of the expected values
is in fact not cost-effective [40,41]. It is this error probability that
is used within the value of information analysis to determine the
potential worth of further research.
Table 1 Available evidence on the costs, QALYs and ICERs of all eight plausible treatment regimens, and adherence to regimens into clinical practice
Treatment regimen Costs* QALYs* ICER Adherence to regimens† (%)
M + P £10,834 (2,206) 0.81 (0.12) — 38
M + P + C £11,008 (2,239) 0.79 (0.14) Dominated 2.8
P £11,227 (3,341) 0.81 (0,13) Dominated 18
D + E £15,036 (1,916) 0.94 (0.17) Extended dominated 1
D + P (3 weekly) £15,883 (1,926) 0.97 (0.15) £32,706 33
D + E + P (70 mg/m2) £16,260 (1,930) 0.86 (0.23) Dominated 0.9
D + E + P (35 mg/m2) £18,460 (1,920) 0.90 (0.17) Dominated 0.9
D + P (weekly) £26,268 (1,945) 0.85 (0.13) Dominated 5
*Information on the mean (standard deviations) costs and QALYs are based on an existing economic model developed to assess the cost-effectiveness of docetaxel for the treatment of mHRPC
for NICE [39].
†Estimates of the adherence to the different treatment regimens are based on a recent audit on the use of chemotherapy regimens for hormone resistant prostate cancer in 33 centers
nationwide undertaken by the British Prostate Group, British Uro-Oncology Group, and British Association of Urological Surgeons [39].
C, clodronate; D, docetaxel; E, estramustine; ICER, incremental cost-effectiveness ratio; M, mitoxantrone; mHRPC, metastatic hormone-refractory prostate cancer; NICE, National Institute for
Health and Clinical Excellence; P, prednisone/prednisolone; QALYs, quality-adjusted life-years.
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We then applied the framework [22] to inform both the 2)
research and 3) implementation decisions. We explored the
pEVPI, pEVPIM, and pEVP over a range of values for l and
interpreted the values at a l of £30,000 per QALY with regard to
their implications for decision-making about resource allocation
and priority setting. For simplicity, we assumed no relationship
between the level of information and the level of implementation
(i.e., the availability and rigor of evidence on different treatment
options is assumed to have no inﬂuence on the adherence to the
treatment regimens into clinical practice ( ′ =ρ ρj j )), and therefore
did not establish the prEVPI. In effect, under this assumption, the
prEVPI equals 0 in all analyses and is noninformative for decision-
making. The implications of this simpliﬁcation are examined
within the discussion.
Finally, we performed univariate sensitivity analyses to
examine whether the valuations for pEVPI, pEVPIM, and pEVP
are sensitive to alternative assumptions related to relevant deci-
sion parameters. Because decision-makers often fail to consider all
relevant alternatives for comparison in health economic evalua-
tions [1,2], we varied the number of treatment options being
considered, using only the three most routinely used treatment
regimens (D + P [3 weekly], M + P, and P) rather than all eight
potential relevant treatment options. We conﬁned ourselves to
brieﬂy discussing the implications of variation in other parameters
(i.e., the levels of implementation, the resulting uncertainty
surrounding the reimbursement decision, the differences in the
expected net beneﬁts between treatment options, and the size of
the eligible patient population) for decision-making about
resource allocation.
Monte Carlo simulations were used to calculate the CEACs
and CEAF, to determine the pEVPI, pEVPIM, and pEVP, and to
conduct the sensitivity analyses. All model calculations were
performed in MS Excel.
Results
Base-case analysis
Reimbursement decision: determining the ICER and identifying
the optimal treatment of mHRPC. An incremental analysis of
the expected costs and QALYs of the eight potential treatments
of mHRPC revealed that the ICER of D + P (3 weekly) compared
to M + P is £32,706 per QALY and the other six treatment
options were (extended) dominated (see Table 1). Thus, depend-
ing on l, decision-makers should reimburse either M + P or
D + P (3 weekly) as standard treatment for mHRPC patients.
Nonetheless, this reimbursement decision is uncertain as illus-
trated by the CEACs showing that the treatment options identi-
ﬁed as cost-effective do not necessarily have the highest
probability of being optimal (see Fig. 1a). Figure 1b illustrates
the CEAF for the reimbursement decision. As noted above, the
discontinuity on the frontier corresponds to the ICER between
the two treatment options, here M + P and D + P (3 weekly). It is
important to note that the comparison of numerous treatment
options results in a relative large extent of uncertainty regarding
the decision about treatment reimbursement.
Research decision and (3) implementation decision: exploring the
pEVPI, pEVPIM, and pEVP. Figure 2 illustrates the relationship
between l and the pEVPI, pEVPIM, and pEVP for all eight
plausible treatment options for mHRPC patients.
The extent of uncertainty regarding the treatment reimburse-
ment decision is formally quantiﬁed in the pEVPI curve. This
curve increases over the full range of values for l, with a local
maximum occurring at the value that corresponds to the ICER
(£32,706 per QALY). In effect, the relative high error probability
(illustrated by the relatively low CEAF [values]), associated with
the reimbursement decision in combination with the substantial
opportunity losses of erroneous decision-making, results in a
considerable maximum return to acquiring more precise esti-
mates of the incremental costs and effects across the range of
plausible treatment options.
Indicating the maximum return to investments in implemen-
tation, the pEVPIM curve initially falls as l rises, with a local
minimum occurring at the value that corresponds to the ICER.
At this value for l, decision-makers are indifferent about which
of the cost-effective treatment regimens (M + P and D + P [3
weekly]) are implemented by health-care professionals. Never-
theless, the pEVPIM at this value does not reach zero because
there is value to be gained from reducing the current adherence to
other treatment options identiﬁed as nonoptimal, i.e., D + E,
M + P + C, D + E + P (70 mg/m2) and D + E + P (35 mg/m2). For
ls larger than the ICER (>£32,706), the pEVPIM rises as a result
of the increasing value to be gained from implementing D + P (3
weekly), which is identiﬁed (with increasing certainty) as the
optimal treatment option.
By summing pEVPI and pEVPIM, we derive the pEVP curve,
which forms a “u-shape.” Over the range of values for l, there is
alternately more, equal or less potential value associated with
research funding than with investments in implementation for
improving the efﬁciency of mHRPC health-care services delivery.
Interpreting the ICER, pEPVI, pEVPIM, and pEVP for a l of
£30,000 per QALY: implications for decision-making about
resource allocation. Given a l of £30,000 per QALY, M + P is
identiﬁed as the cost-effective treatment of mHRPC. Assuming
perfect implementation, the expected value of the decision to
reimburseM + P, based purely on current information, is £13,575
per patient, although the expected value of a decision based on
perfect information is £16,817 per patient. With a UK population
of 4122 mHRPC patients, the pEPVI is estimated to be £13.4
million. Considering the variation in clinical practice and current
adherence to M + P (38%), the expected value of reimbursing
M + P without ensuring its implementation is £12,517 per patient
(i.e., the sum of the proportionate expected values of all eight
treatment regimens currently utilized by health-care profession-
als). As a result, there is an estimatedworth of £1058 (= £13,575 -
£12,517) per patient in investing in strategies to promote perfect
implementation of M + P. Translated to population values, the
pEVPIM and pEVP are £4.4 million and £17.7 million, respec-
tively. In effect, at this value of l there appears to be considerable
scope for improving the efﬁciency of health-care provision for
mHRPCpatients; there is considerablymore value associatedwith
conducting further research than investing in implementation
strategies but both are potentially worthwhile.
Sensitivity analysis
Implications of varying the (number of) treatments being
compared. Figure 3 shows the CEAF, pEVPI, pEVPIM, and
pEVP as a function of l, considering only the three most
routinely used treatments of mHRCP: D + P (3 weekly), M + P,
and P. Compared with a plausible range of eight treatment
options (see Fig. 2), there is less uncertainty, with the same deci-
sion switch point, associated with identifying the optimal option
from three treatment regimens. Consequently, the maximum
expected return to further research (pEVPI) is less. Because we
consider the most routinely used treatment regimens and assume
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no change in their implementation into clinical practice, the
pEVPIM remains relatively constant and hence the combined
measure of the expected maximum return to resources commit-
ted to further research and/or implementation strategies (pEVP)
is also reduced. Given a l of £30,000 per QALY, the pEVPI,
pEVPIM, and pEVP are £6.8 million, £1.6 million, and £8.4
million, respectively. Evidently, by limiting their decision options,
decision-makers might underestimate the uncertainty surround-
ing the decision about which treatment to reimburse. The formal
quantiﬁcation of the reduction in decision uncertainty in terms of
diminished expected value of acquiring additional information
might be misleading, veiling that there is a clear risk of omitting
cost-effective treatments options and making inappropriate deci-
sions about the use of health-care resources.
Implications of varying other decision parameters. In addition,
we performed various sensitivity analyses, not reported here, to
examine the inﬂuence of the levels of implementation, the result-
ing uncertainty surrounding the reimbursement decision, the dif-
ferences in the expected net beneﬁts between treatment options
and the size of the eligible patient population on the expected
population values of information and implementation. Evidently,
varying the levels of implementation did not change the expec-
tations regarding the decision about which treatment to reim-
burse or the question of whether to gather more information to
inform this decision. Nevertheless, a reduction or increase in the
level of adherence to the cost-effective treatment options (M + P
or D + P [3 weekly]) implied larger or lower monetary payoffs
from investments in implementation strategies to change clinical
practice, respectively. Changes in the degree of uncertainty
surrounding the reimbursement decision only impacted on the
maximum expected return to further research—the pEVPI
increased or decreased dependent on the set of unknown param-
eters q; the decision about which treatment regimen to reimburse
remained unchanged. Varying the extent of the expected incre-
mental net beneﬁts of the different options to treat mHRPC
altered the amplitude of all curves and shifted the decision switch
point (i.e., the ICER). Variations in the size of the eligible patient
population affected only the altitude of the curves, i.e., the larger
the population for whom decisions are relevant, the larger the
values of pEPVI, pEVPIM, and pEVP.
In general, the results of the sensitivity analyses indicated that
it is important for decision-makers to consider uncertainty and
variation in decision parameters when making resource alloca-
tion decisions and to include all possible treatment alternatives,
even those that are not expected to be cost-effective.
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Figure 1 (a) Cost-effectiveness acceptability
curves for the eight plausible treatment regimens
for mHRPC. (b) Cost-effectiveness acceptability
frontier (CEAF) for the reimbursement decision
involving the eight plausible treatment options for
mHRPC. mHRPC, metastatic hormone-refractory
prostate cancer.
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Discussion
Main Findings of the Analysis
To provide an efﬁcient allocation of health-care resources for
mHRPC in the UK, we applied an analytic framework [22], which
informs the separate but related decisions about: 1) treatment
reimbursement; 2) research funding; and 3) implementation
investment. Depending on the cost-effectiveness threshold (l), we
identiﬁed mitoxantrone plus prednisone/prednisolone (M + P)
and docetaxel plus prednisone/prednisolone (D + P [3 weekly])
(for a l of £32,706 per QALY) as the optimal treatments for
mHRPC patients. The use of the six other chemotherapy and
nonchemotherapy treatment options considered are found not to
be cost-effective. As illustrated in the CEACs and CEAF, the
reimbursement decision is associated with a large degree of uncer-
tainty. This decision uncertainty is formally quantiﬁed in the
expected population value of perfect information (pEVPI), indi-
cating an estimated maximum return to acquiring additional
economic evidence on the range of plausible treatment options of
£13.4 million (given a l of £30,000 per QALY). Considering the
current variation in clinical practice and a l of £30,000 perQALY,
there is potentially additional value associated with enhancing
adherence by health-care professionals to the cost-effective treat-
ment regimen(s) (M + P or D + P [3 weekly]), with the expected
population value of perfect implementation (pEVPIM) estimated
to be £4.4 million. Providing a combined measured of the total
opportunity losses due to inefﬁciencies in health-care services
delivery, the expected value of perfection (pEVP) of £17.7 million
underlines that there is considerable scope for improvement.
Use and Interpretation of the Main Findings
Although the pEVPI and pEVPIM indicate that there is substan-
tially more value associated with acquiring additional informa-
tion than with ensuring the implementation of optimal treatment
regimens for mHRPC, the costs of further research and that of
speciﬁc implementation strategies need to be taken into account
when deciding about the allocation of scarce health-care
resources for research and/or implementation purposes. That is,
to establish the potential worth of research funding and/or
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Figure 2 Cost-effectiveness acceptability frontier
(CEAF) (primary axis) and population expected
values of perfect information (pEVPI), perfect imple-
mentation (pEVPIM), and perfection (pEVP) (sec-
ondary axis) for the adoption decision between the
eight plausible treatment regimens for mHRPC.
mHRPC, metastatic hormone-refractory prostate
cancer.
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Figure 3 Cost-effectiveness acceptability frontier
(CEAF) (primary axis) and the population expected
values of perfect information (pEVPI), perfect imple-
mentation (pEVPIM), and perfection (pEVP) (second-
ary axis) for the adoption decision between the
three most routinely used treatment regimens for
mHRPC. mHRPC, metastatic hormone-refractory
prostate cancer.
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investments in implementation, the total research and implemen-
tation costs need to be estimated and balanced against the
pEVPI and pEVPIM, respectively. Assuming that research costs
do not exceed the pEVPI (estimated to be over £13 million), it is
potentially cost-effective to fund further research to reduce uncer-
tainty surrounding the decision about mHRPC treatment reim-
bursement. In addition, if the expected costs of implementation
strategies to change guidance adherence by health-care profes-
sionals are less than the pEVPIM (estimated to be over £4
million), then it is potentially cost-effective to ensure the imple-
mentation of cost-effective health-care technologies into clinical
practice. Given a l of £30,000 per QALY, we would recommend
reimbursement of M + P alongside commissioning of further
research and investment in implementation efforts for improving
the efﬁciency of health-care services delivery for mHRPC
patients.
Through sensitivity analyses, we found that the valuations
for the pEVPI, pEVPIM, and pEVP are mainly driven by l, the
number of (plausible) treatment options being considered, the
current level of implementation, and the size of the eligible
patient population. Consequently, resource allocations decisions
will be substantially different for different health-care technology
decisions.
Use and Practicality of the Framework
The application demonstrates that the framework provides a
simple and useful decision analytic tool for decision-makers to
address resource allocation problems between health-care provi-
sion, further research, and adopting implementation strategies. It
allows decision-makers to establish the potential worth (quanti-
ﬁed in terms of value of information and value of implementation)
of alternative uses of health-care resources in an explicit and
transparent way. By altering the framework parameters and/or
assumptions, the analytic framework will be applicable to differ-
ent localities, involving varying settings, patient populations, and
health-care technologies, costs and effects data, and implementa-
tion levels. Of course, in applying the framework to appropriately
inform resource allocation decisions, it remains important that
decision-makers follow methodological guidelines for health eco-
nomic evaluation, including economic evaluation design, data
collection, and data analysis and interpretation of results [1,2,5].
Although the analytic framework might aid any decision-maker
facing problems concerning resource allocation, its most valuable
application seems to be in informing policy decisions about the
efﬁcient use of health-care resources at a health-care system level
for (national) decision-making bodies such as NICE or even
(international) pharmaceutical companies.
Limitations of the Framework
Notwithstanding the practical signiﬁcance and merits of the
framework, some comments have to be made when using it and
interpreting the results for resource allocation decision-making.
First, controversy exists about whether reimbursement decisions
should be based only on the mean net beneﬁts, irrespective of
whether differences are statistically signiﬁcant or fall outside a
Bayesian range of equivalence [23]. Eckermann and Willan [25]
have recently demonstrated that the EVSI is reduced by the costs
of reversal with technology reimbursement and trialing. Conse-
quently, they argue that optimal trial design and decision-making
in a common case of interest (where there is evidence of positive
but uncertain net beneﬁt of a health-care technology) requires
consideration of the option to delay decisions about reimburse-
ment and trial aswell as reimbursing and trial, despite opportunity
costs of delay. Second, it is reiterated that the framework estab-
lishes only the necessary conditions for deciding on acquiring
more information and/or ensuring implementation, providing an
indication of whether such investments have the potential to be
worthwhile. The sufﬁcient condition for efﬁcient resource alloca-
tion requires the valuation and comparison of the expected ben-
eﬁts (i.e., EVSI and EVSIM) and expected costs associated with
speciﬁc investments in further research [7,8,23–25] and/or imple-
mentation strategies [26,27]. Finally, within the framework, it is
assumed that the current level of implementation (i.e., adherence
to guidance) is ﬁxed and known and that no relationship exists
between the level of information and that of implementation. This
is clearly an oversimpliﬁcation for the purposes of introducing the
framework. More realistically, it is likely that the level of imple-
mentation is a function of the level of information and that the
provision of information would alter the adherence to health-care
technology guidance, for instance through publication of research
evidence. It is important to notice that this is not necessarily a
straightforward relationship where more information leads to
better levels of implementation. Situations could be envisaged
where more information could lead to less implementation, for
example when health-care professionals react to new information
that suggests a treatment option is effective while ignoring the
information that the treatment is not cost-effective.
Suggestions for Framework Extension
There are several ways in which the framework could be
extended to account for its limitations. First of all, decision-
making could potentially be improved by allowing for the cost
of reversal within the framework and incorporating an explicit
ordering of preferences for technology reimbursement between
the viable options: 1) to delay and research; 2) to reimburse and
research; and 3) to reimburse with no research. This approach
has been described in more detail by Eckermann and Willan
[25]. Second, it is also possible that technology reimbursement
has an impact on the prospects of acquiring certain types of
evidence to support its use in the future, because the incentives
to conduct evaluative research are removed and even if public
resources are made available, further experimental research may
be regarded as unethical. Therefore, the decision to reimburse a
technology ought to take account of both the value of reimburs-
ing the technology (i.e., its mean net beneﬁt) and the value of the
type of evidence (e.g., evidence of the relative effect that would
require experimental design) that may be forgone [28]. A third
suggestion for extension would be for the framework to set out
both the necessary and sufﬁcient conditions for informing the
research and implementation decision. That is, the EVPI could
be calculated for individual or various combinations of param-
eters to assess the potential worth of research concerning par-
ticular elements of the decision (so-called partial EVPI or EVPPI)
[3,23]. Moreover, the value of information framework could
be extended to establish the EVSI to identify whether speciﬁc
research is cost-effective and/or to aid in efﬁcient research
design. In the same manner, the value of implementation frame-
work could be extended to determine the expected worth of
speciﬁc implementation strategies (through EVSIM) and/or to
aid in the design of efﬁcient strategies to improve implementa-
tion. Finally, the framework could be adapted to incorporate the
functional and dynamic relationship between the level of infor-
mation and the level of implementation of health-care tech-
nologies and to include the uncertainty about the adherence
to technology guidance. For the suggested extensions to be
included within the framework, it would need to be expanded
beyond the simple four-state world presented here, to allow for
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postinformation and postimplementation states which are less
than “perfect.”
Conclusions
In a budget-constrained health-care system, decisions regarding
investment in implementation strategies must be made alongside
those regarding investment in health-care provision and further
research. We demonstrate that the application of the framework
developed by Fenwick et al. [22] could aid decision-makers
in addressing complex issues of priority setting and resource
allocation.
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